Otsuka Pharmaceutical Company, Limited

Educational Foundation Jichi Medical University

Masanori Kawasaki

Makoto Matsumoto

Yoshihiro Goto

Norimitsu Hariguchi

Shigeto Yoshida

Hiroyuki Hashizume

Masami Mizukoshi

Tatsuo Tomishige

Yoshio Ohba

Hirofumi Sasaki

Shin Miyamura

Hidetsugu Tsubouchi

Masahiro Saito

Takumi Sumida

Motohiro Itotani

Yoshikazu Haraguchi

Takeshi Hasegawa

Kuniko Hirota

Katsuya Inagaki

Takeshi Kuroda

Kuninori Tai

Hideaki Kuroda

Isao Takemura

Takayuki Matsuzaki

Makoto Komatsu

Kinue Ohguro

Yoshihiko Shimokawa

Kazuho Tanaka

Yuji Seike

Hiroyuki; Daiaparesu 1401 Hashizume

Takeshi; Daiichiaijitsuhaitsu 607 Hasegawa

Shin; 147-13 Mukaininokoshi Miyamura

The present invention provides a novel transfer vector and a recombinant baculovirus; methods for the production thereof; pharmaceuticals containing the recombinant baculovirus as an active ingredient, which are useful as preventive or therapeutic drugs for infectious diseases such as malaria and influenza; and methods for preventing and treating infectious diseases such as malaria and influenza. More specifically, the invention provides a recombinant transfer vector capable of expressing a foreign gene fused to a virus gene under the control of a dual promoter; a recombinant baculovirus; methods for the production thereof; pharmaceuticals containing the recombinant baculovirus as an active ingredient; and methods for preventing and treating infectious diseases such as malaria and influenza comprising administrating the recombinant baculovirus to patients.

Recombinant baculovirus vaccine

A recombinant transfer vector capable of expressing a foreign gene fused to a viral gene under the control of dual promoters and a recombinant baculovirus, and methods for production thereof, as well as pharmaceuticals comprising the recombinant baculovirus as an active ingredient.

The present invention provides antituberculous therapeutic drugs with a higher potency. The present invention provides also antituberculous therapeutic drugs containing oxazole compounds represented by (I) general formula (1): [wherein Rrepresents a hydrogen atom or C1-6 alkyl group, n represents an integer of 0-6, and Rrepresents general formula (A) or the like, wherein Rrepresents a phenoxy group (at least one group selected from the group consisting of a halogen atom, an optionally halogen-substituted C1-6 alkyl group and an optionally halogen-substituted C1-6 alkoxy group may be substituted on the phenyl ring) or the like], optically active forms thereof or salts thereof, and drugs (II) such as primary antituberculous drugs. 

Antituberculous composition comprising oxazole compounds

The present invention provides a 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound represented by the following general formula: (1) in the above formula (1), R1 represents a hydrogen atom or C1-C6 alkyl group, n represents an integer of 0 to 6, R1 and &#x2014;(CH2)nR2 may form a spiro ring represented by the formula (30) below, together with the adjacent carbon atom (in the formula below, RRR represents a piperidyl group which may have substituents on the piperidine ring), (30) and R2 represents a benzothiazolyloxy group, quinolyloxy group, pyridyloxy group or the like. The present compound has an excellent bactericidal action against, multi-drug-resistant, and atypical acid-fast bacteria. 

2,3-dihydro-6-nitroimidazo (2,1-b) oxazole compounds for the treatment of tuberculosis

The present invention provides a 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound represented by the following general formula: wherein Rrepresents a hydrogen atom or C1-C6 alkyl group, n represents an integer of 0 to 6, Rrepresents a group &#x2014;ORor the like, and Rrepresents a hydrogen atom, C1-C6 alkyl group or the like, or Rand &#x2014;(CH)Rmay bind to each other together with carbon atoms adjacent thereto through nitrogen atoms so as to form a spiro ring represented by the general formula (H): wherein Ris hydrogen, C1-C6 alkyl group or the like. The present compound has an excellent bactericidal action against, multi-drug-resistant, and atypical acid-fast bacteria.

2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles

Growing community of inventors

Tokushima, Japan

Masanori Kawasaki